Colonic Physiology

Companion piece to Colorectal Anatomy & Embryology (gross/embryologic anatomy, from ASCRS Ch. 1) and Small Intestine Anatomy & Physiology (the small-bowel equivalent, from Sabiston) — this page covers colonic wall histology, absorptive/secretory physiology, innervation, motility, and the microbiome, synthesized from ASCRS Ch. 2. Textbook reference content, not primary literature.

Embryology (brief — see Colorectal Anatomy & Embryology for the full account)

This chapter's embryology section substantially overlaps with Colorectal Anatomy & Embryology's Embryology section (same midgut rotation/herniation story) — no new content there. It does add detail on anorectal embryology timing not previously captured: the cloaca (endoderm + ectoderm) divides during week 6 into anterior urogenital and posterior anorectal/sphincter components via caudal migration of the urogenital septum; the external anal sphincter forms in the posterior cloaca around week 10 (concurrent with midgut return to the abdomen); the internal anal sphincter forms later, around week 12, by enlargement/specialization of the rectum's circular smooth muscle layer. This timing detail has been added to Colorectal Anatomy & Embryology's Embryology section directly rather than duplicated here.

Colonic wall histology

Four layers, as elsewhere in the GI tract: mucosa (epithelium + lamina propria + muscularis mucosae), submucosa (loose connective tissue, vasculature, lymphatics, Meissner's plexus), muscularis propria (circular inner layer, continuous cecum-to-anal-canal, thickening distally to form the internal anal sphincter; longitudinal outer layer, concentrated into the three taeniae coli from cecum to rectum before fanning into a continuous coat), and serosa (outermost, visceral peritoneum). Auerbach's (myenteric) plexus sits between the circular and longitudinal muscle layers. The interstitial cells of Cajal (ICC) are specialized c-kit-positive mesenchymal cells that serve as the pacemaker cells of the enteric nervous system, electrochemically linking the submucosa to the myenteric plexus — multiple ICC subtypes exist and their distribution is still debated. ICC are the presumed cell of origin for GI stromal tumors (GISTs), which therefore arise from the colonic wall rather than the mucosa.

Three epithelial cell types: enterocytes (simple columnar, the major absorptive/secretory cell type), goblet cells (mucus secretion), and neuroendocrine cells (chemoreceptors, detect luminal threats, initiate protective responses). Enterocytes and goblet cells together comprise ~95% of colonic epithelium. All types differentiate from common stem cells at the crypt base and migrate to the surface; the epithelium turns over every 4–5 days. Crypt epithelium is proliferative/secretory (chloride); surface epithelium is differentiated/absorptive — ion transport occurs at both levels.

Secretory and absorptive physiology

The colon receives ~1500–2000 mL of ileal effluent daily and absorbs all but ~100 mL fluid and 1 mEq sodium/chloride, producing feces with ~30 mmol/L sodium and ~75 mmol/L potassium. Absorptive capacity can compensate up to 5–6 L and 800–1000 mEq sodium/day when challenged (e.g., by small-bowel malabsorption) — the proximal colon is the primary site of this compensatory storage/mixing/absorption function (established since Cannon, 1902); the rectosigmoid functions primarily as a conduit but can also participate.

Sodium: actively absorbed (90%) in exchange for potassium secretion, via Na⁺/K⁺-ATPase (3 Na⁺ out: 2 K⁺ in per cycle) plus tightly coupled electroneutral Na⁺/H⁺ and Cl⁻/HCO₃⁻ exchange in the proximal colon, and epithelial sodium channel (ENaC)-mediated absorption in the distal colon. Chloride is absorbed via luminal CFTR and other apical mechanisms (KCCl cotransporter, Cl⁻ channels, Cl⁻/HCO₃⁻ exchangers). Net result: tight regulation of proximal-vs-distal colonic electrolyte transport (see Fig. 2.4 in the source PDF for the full channel schematic) — clinically relevant to C. difficile (inhibits Na⁺/H⁺ exchange) and cholera toxin (drives cAMP-mediated active Cl⁻/HCO₃⁻ secretion, causing secretory diarrhea).

Potassium: net secretion in the colon; prolonged diarrhea → hypokalemic metabolic acidosis (contributing to alkaline stool pH).

Aldosterone: decreases fecal sodium concentration (30→2 mEq/L) and increases potassium (75→150 mEq/L) by two distinct mechanisms — activating epithelial Na⁺-K⁺-ATPase in the distal colon, and activating Na⁺/H⁺ exchange in the proximal colon.

Water absorption: nominal mucosal surface area ~2000 cm², effectively larger because crypt cells absorb as well as secrete. Stool water is hypertonic to plasma (350–400 mOsm/L) because colonic bacterial solute production outpaces the epithelium's water permeability; net absorption results because more fluid moves lumen→blood than blood→lumen. Adrenergic (α-receptor) and anticholinergic stimuli increase absorption.

Short-chain fatty acid (SCFA) absorption: proximal-colon bacterial fermentation of carbohydrates produces acetate, propionate, and butyrate — butyrate is the colonic epithelium's main energy substrate, supplying ~10% of daily caloric requirements. SCFA potently stimulate sodium/chloride/water absorption (butyrate most effective); reduced fecal SCFA in acute diarrhea may impair sodium absorption. Proposed therapeutic relevance: reducing inflammation in ulcerative colitis and diversion colitis, and a hypothesized (not established) protective effect against colon cancer.

Vitamin K absorption: dietary (small-bowel, carrier-mediated, energy-dependent) vs. microbiota-generated colonic vitamin K (passive diffusion) — two distinct absorptive routes for the same vitamin.

Colonic innervation

Extrinsic: sympathetic input (proximal colon via the superior mesenteric ganglion, distal colon via the inferior mesenteric ganglion; distal rectum/anal canal via hypogastric-plexus fibers) is net-inhibitory to colonic motor function, via strong tonic inhibitory drive to submucosal secretomotor neurons (α-2-adrenergic) and direct sphincter contraction. Parasympathetic input is excitatory and runs two routes: vagal (cecum, ascending, transverse colon) and pelvic-nerve/sacral (descending colon, sigmoid, rectum) — pelvic nerves enter near the rectosigmoid junction and project both orally/aborally within the myenteric plexus plane. The external anal sphincter (striated) is separately innervated by the somatic pudendal nerve.

Intrinsic: the enteric nervous system (200–600 million neurons, the largest single ANS division) comprises the myenteric (Auerbach's, smooth-muscle function) and submucosal (Meissner's, ion transport) plexuses — congenitally absent in both in Hirschsprung's disease (see Colorectal Anatomy & Embryology's embryology section), producing aganglionic segments that fail to relax, disrupting peristalsis and causing severe constipation.

Key neurotransmitters: acetylcholine (ACh) and tachykinins (substance P) are the major excitatory mediators; nitric oxide (NO), vasoactive intestinal peptide (VIP), and possibly ATP are the major inhibitory mediators. Pudendal-nerve-to-external-sphincter transmission is cholinergic (ACh).

Pain

Rectal pain is mediated primarily via pelvic afferent pathways. Inflammation can sensitize both the response properties of specific sensory neuron classes and the ascending pathways involved — relevant to post-inflammatory hypersensitivity and postinfectious IBS. Visceral sensory neurons organize into three central pathways (vagal, thoracolumbar, lumbosacral); distension of the descending/sigmoid colon is perceived as cramping, gas, or pressure in the lower abdomen/back/perineum. IBS pathogenesis involves both peripheral sensory alterations and disturbed central processing (brain-gut axis dysregulation); decreased epithelial expression of the serotonin transporter (SERT) is associated with IBS in many studies, though causality is unclear.

Colonic motility

Two categories of contractile events: segmental contractions and propagated contractions (including low-amplitude propagating contractions, LAPC, and high-amplitude propagating contractions, HAPC — HAPC's main function is propagating colonic contents toward the anus). Tone (a more prolonged contractile state, actin-myosin-mediated rather than slow-wave-mediated) governs accommodation/storage/distribution and shows diurnal variation — increasing after meals, decreasing during sleep, increasing dramatically on waking. The colonic motor response to eating begins within minutes and lasts up to 3 hours, driven more by caloric/fat/carbohydrate content than protein (which inhibits motor activity). Regular contractile bursts ("colonic motor complexes") occur roughly 1–2 times/hour, lasting ~6 minutes; cyclic rectal motor complexes are evident but not synchronized with small-bowel migrating motor complexes, and their precise function/regulation is unclear.

Defecation physiology: rectal filling generates a fullness sensation via rectal afferents and induces the rectoanal inhibitory reflex, allowing the individual to sense and postpone/proceed. See Anorectal Physiology for the full mechanistic account of the RAIR, sphincter roles, and the defecation sequence — that page (ASCRS Ch. 3) supersedes the brief treatment previously here. Per that page, the internal sphincter provides ~50–70% of resting anal tone (plus ~15% from hemorrhoid complexes), broadly consistent with this chapter's own "~80%" framing.

Modulators of colonic motility

Pharmacologic and neuromodulatory levers, several relevant to Constipation's medical management section (which names lubiprostone, linaclotide/Linzess, and prucalopride/Motegrity as options without detailing mechanism — mechanism detail below fills that gap):

Muscarinic agonists/cholinesterase inhibitors (hyoscamine, neostigmine) increase motility; α-2 antagonist yohimbine increases motility and fluid/electrolyte absorption; α-2 agonist clonidine reduces motility, tone, and phasic pressure (useful for diarrhea-predominant IBS).
5-HT₃ antagonists (alosetron) increase compliance, reduce postprandial rectal motor activity, and reduce rectal sensitivity in IBS — approved for IBS-D in women but carries an ischemic colitis signal (0.15% vs 0.0% placebo in an FDA adverse-events review), leading to market withdrawal at one point.
5-HT₄ agonist prucalopride accelerates intestinal/colonic transit in chronic constipation without the QT-interval effect of older agents in its class.
Opioids act on µ receptors predominantly, reducing neuronal excitability/neurotransmitter release, increasing colonic phasic segmental activity, reducing fasting tone, attenuating the gastrocolonic response, and increasing fluid absorption/mucosal contact time — opioid-induced constipation affects 41–81% of treated patients.
Lubiprostone (a prostaglandin E1-derived bicyclic fatty acid) activates apical ClC-2 chloride channels and CFTR, causing intestinal fluid secretion; accelerates transit but doesn't itself affect colonic motor activity. FDA-approved for chronic constipation and constipation-predominant IBS.
Bile acids (e.g., chenodeoxycholic acid) infused into the sigmoid/rectum stimulate phasic contractions and rectal sensitivity; disrupted enterohepatic bile-acid circulation (Crohn's disease, ileal resection, radiation ileitis, or idiopathic bile-acid malabsorption) can cause diarrhea via this mechanism — potentially explaining diarrhea in a subset of IBS patients.
Laxatives: osmotic (PEG, magnesium citrate, sodium phosphate, nonabsorbable carbohydrates — pull fluid into the lumen) vs. stimulant (bisacodyl, sodium picosulfate, glycerol — stimulate HAPC wave sequences/mass movements; bisacodyl and sodium picosulfate also have anti-absorptive/secretory effects). Bisacodyl's motor effect is mediated through mucosal afferent nerve fibers (blockable by topical mucosal lidocaine).
Sacral nerve stimulation — FDA-approved for fecal incontinence; role in constipation is unclear, but S3-root stimulation induces pan-colonic propulsive activity and has increased stool frequency in slow-transit constipation in small studies (in one series, 20/27 patients had delayed transit pre-stimulation, only 9/27 post-stimulation).

Microbiome

The adult human intestine hosts ~110 trillion bacteria, dominated by two phyla, Firmicutes and Bacteroidetes (together >98% of gut bacteria in many studies). Composition is diet/lifestyle/ health-modulated, established early in life, and relatively resistant to change thereafter; microbial diversity is generally used as a "healthy microbiota" index, though this is called a simplistic notion (some beneficial plant foods decrease diversity yet increase host benefit).

Disease associations: fecal/mucosal microbiome composition is altered in IBS, IBD, colorectal cancer, and autism, implicating dysbiosis in pathogenesis (though for constipation/diarrhea specifically, whether this reflects cause or effect is unclear). Roseburia spp. are decreased in IBD, motivating interest in microbiota manipulation (antibiotics, probiotics, prebiotics) as therapy. Crohn's disease (CD) is associated with lower overall microbial diversity than healthy controls; abundance of both Proteobacteria and Bacteroidetes was significantly higher in CD than in healthy controls and than in ulcerative colitis. Ulcerative colitis (UC) is associated with low numbers/absence of Faecalibacterium prausnitzii, a common healthy-gut community member.

Flag — direction-of-change discrepancy with Crohn Disease: that page's Risk factors section (sourced from Sabiston) describes CD dysbiosis as "decreased Bacteroides/Firmicutes, increased Gammaproteobacteria/Actinobacteria." This chapter instead reports Bacteroidetes (same phylum, alternate spelling) as significantly higher, not lower, in CD vs. healthy controls and vs. UC. Both are textbook-level, non-primary sourcing; gut microbiome literature on IBD dysbiosis is genuinely heterogeneous across cohorts/methods, so this may reflect real study-to-study variability rather than an error in either textbook — flagging per this wiki's practice rather than silently picking one. Worth a primary-literature or systematic-review source if Stephen wants this resolved. Update: ASCRS Ch43 - Inflammatory Bowel Disease Pathobiology independently reports decreased Bacteroidetes in IBD generally, agreeing with Crohn Disease's original figure rather than this page's — now 2 sources against 1, but still not treated as resolved given the cohort/methodology heterogeneity noted above.

Antibiotic exposure (e.g., fluoroquinolones) can durably alter gut microbiome diversity/richness/ evenness — in one cited study, ~1/3 of species present changed after ciprofloxacin, taking up to 6 months to rebound, with broad-spectrum/anti-anaerobic agents causing the longest-lasting shifts. The NIH Human Microbiome Project (Phase II) specifically targets IBD as one of three microbiome-associated conditions under active study (alongside preterm birth and type 2 diabetes).

Colorectal Anatomy & Embryology — gross anatomy/embryology this page's histology and physiology build on; received the anal-sphincter embryologic-timing addition noted above.
Small Intestine Anatomy & Physiology — the small-bowel analog (Sabiston-sourced); together these two pages now cover GI physiology end to end from duodenum through anal canal.
Constipation — medical-management section that this page's Modulators-of-motility section adds mechanistic depth to.
Crohn Disease — microbiome dysbiosis discrepancy flagged above.
Anorectal Physiology — full mechanistic account of the RAIR and defecation sequence only summarized briefly here.
Anorectal Physiology Testing — diagnostic-testing counterpart to the rectoanal inhibitory reflex and defecation-physiology content here.

Open items / gaps

The Crohn's disease Bacteroidetes-direction discrepancy (flagged above) is unresolved and would benefit from a primary IBD-microbiome source.
Hirschsprung's disease is referenced here and in Colorectal Anatomy & Embryology but still has no dedicated wiki page — flagged as a gap in both places now.
Rectal motor complexes' function/regulation is explicitly described as unclear in the source itself — not a wiki gap, just an open question in the field.

Colorectal LLM Wiki